Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ivermectin, a widely used endectocide, holds promise for malaria control by rendering blood-feeding Anopheles mosquitoes lethal, suggesting potential for mass drug administration (MDA) and mass ivermectin treatment of livestock (ITL). Discovered in 1973 from Streptomyces avermitilis , ivermectin targets glutamate-gated chloride ion channels, offering a novel mechanism against malaria vectors. Initial studies demonstrated significant Anopheles mortality when feeding on ivermectin-treated hosts, with field trials confirming reduced mosquito survival. Regional research highlights varied impacts, with significant reductions in key malaria vectors across Africa, Latin America and South-east Asia. Beyond lethality, ivermectin's sublethal effects include delayed feeding, inhibited parasite development and reduced fecundity, which collectively diminish malaria transmission. Combining ivermectin with antimalarials like dihydroartemisinin-piperaquine (DP) enhances mosquito mortality, while ITL provides a viable strategy for outdoor-feeding vectors. This chapter explores ivermectin's multifaceted role in accelerating global malaria elimination efforts.

Original publication

DOI

10.1079/9781789248845.0007

Type

Chapter

Book title

Practical Control of Mosquito Disease Vectors

Publication Date

23/12/2024

Pages

139 - 165